Metelimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.[1] It was dropped from further development in favour of fresolimumab,[2] which is currently being developed by Genzyme.[3]
History
Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]
Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which is currently being developed by Genzyme.[3]
References
- ^ http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=860002&p_IsPs=N
- ^ a b https://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html
- ^ a b "Archived copy". Archived from the original on 2006-09-02. Retrieved 2009-07-27.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ http://prnwire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-28-2000/0001324438&EDATE=
- ^ http://www.drugdiscoveryonline.com/article.mvc/Cambridge-Antibody-Genzyme-to-collaborate-on-0001?VNETCOOKIE=NO
- ^ http://goliath.ecnext.com/coms2/gi_0199-693661/CAT-192-is-safe-but.html
- ^ "Archived copy". Archived from the original on 2012-02-25. Retrieved 2009-07-27.
{{cite web}}: CS1 maint: archived copy as title (link)
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |